Mauro Mansutti

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.2K citations

Noah Trial, Breast Oncology, Oncology +7

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Luca Gianni, Gilles Romieu, Sérgio Serrano et al. · Journal of Clinical Oncology · 2013 · 255 citations · Full text

First-line Therapy, Breast Oncology, Medicine +13

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Luca Gianni, Giancarlo Bisagni, Marco Colleoni et al. · The Lancet Oncology · 2018 · 167 citations

Breast Oncology, Medicine, Pharmacology +7

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Luca Gianni, Mauro Mansutti, Antonio Antón et al. · JAMA Oncology · 2018 · 153 citations · Full text

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Lucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni et al. · The Lancet Oncology · 2021 · 82 citations

Breast Oncology, Oncology, Postmenopausal Patients +9